ITMI20081652A1 - TRANSDERMIC COMPOSITIONS FOR HYPOSENSIBILIZING SPECIFIC IMMUNOTHERAPY - Google Patents
TRANSDERMIC COMPOSITIONS FOR HYPOSENSIBILIZING SPECIFIC IMMUNOTHERAPY Download PDFInfo
- Publication number
- ITMI20081652A1 ITMI20081652A1 IT001652A ITMI20081652A ITMI20081652A1 IT MI20081652 A1 ITMI20081652 A1 IT MI20081652A1 IT 001652 A IT001652 A IT 001652A IT MI20081652 A ITMI20081652 A IT MI20081652A IT MI20081652 A1 ITMI20081652 A1 IT MI20081652A1
- Authority
- IT
- Italy
- Prior art keywords
- compositions
- hyposensibilizing
- transdermic
- specific
- therapy
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims description 10
- 238000009169 immunotherapy Methods 0.000 title claims description 9
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 claims description 16
- 230000001694 hyposensitizing effect Effects 0.000 claims description 10
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims description 8
- 229960004889 salicylic acid Drugs 0.000 claims description 8
- 230000002209 hydrophobic effect Effects 0.000 claims description 7
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 7
- 239000002671 adjuvant Substances 0.000 claims description 6
- 235000019271 petrolatum Nutrition 0.000 claims description 5
- 239000000427 antigen Substances 0.000 claims description 3
- 102000036639 antigens Human genes 0.000 claims description 3
- 108091007433 antigens Proteins 0.000 claims description 3
- 238000002560 therapeutic procedure Methods 0.000 description 10
- 239000013566 allergen Substances 0.000 description 8
- 210000003491 skin Anatomy 0.000 description 7
- 241000209504 Poaceae Species 0.000 description 4
- 230000000172 allergic effect Effects 0.000 description 4
- 208000010668 atopic eczema Diseases 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 239000000902 placebo Substances 0.000 description 4
- 229940068196 placebo Drugs 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 3
- 210000003630 histaminocyte Anatomy 0.000 description 3
- 230000036647 reaction Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 229960005486 vaccine Drugs 0.000 description 3
- 238000012795 verification Methods 0.000 description 3
- 229960004784 allergens Drugs 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 210000004207 dermis Anatomy 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- ZKLPARSLTMPFCP-UHFFFAOYSA-N Cetirizine Chemical compound C1CN(CCOCC(=O)O)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZKLPARSLTMPFCP-UHFFFAOYSA-N 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 206010010744 Conjunctivitis allergic Diseases 0.000 description 1
- 241000238424 Crustacea Species 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 241000219428 Fagaceae Species 0.000 description 1
- 208000004262 Food Hypersensitivity Diseases 0.000 description 1
- 206010016946 Food allergy Diseases 0.000 description 1
- 208000005577 Gastroenteritis Diseases 0.000 description 1
- 208000001718 Immediate Hypersensitivity Diseases 0.000 description 1
- 208000007811 Latex Hypersensitivity Diseases 0.000 description 1
- 241000237852 Mollusca Species 0.000 description 1
- 241000207834 Oleaceae Species 0.000 description 1
- 208000036071 Rhinorrhea Diseases 0.000 description 1
- 206010039101 Rhinorrhoea Diseases 0.000 description 1
- 206010039251 Rubber sensitivity Diseases 0.000 description 1
- 206010040914 Skin reaction Diseases 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- 241000218215 Urticaceae Species 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 230000002009 allergenic effect Effects 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 235000020932 food allergy Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229940046528 grass pollen Drugs 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 201000005391 latex allergy Diseases 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- WOFMFGQZHJDGCX-ZULDAHANSA-N mometasone furoate Chemical compound O([C@]1([C@@]2(C)C[C@H](O)[C@]3(Cl)[C@@]4(C)C=CC(=O)C=C4CC[C@H]3[C@@H]2C[C@H]1C)C(=O)CCl)C(=O)C1=CC=CO1 WOFMFGQZHJDGCX-ZULDAHANSA-N 0.000 description 1
- 229940003691 nasonex Drugs 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 230000010152 pollination Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000001932 seasonal effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 231100000430 skin reaction Toxicity 0.000 description 1
- 230000035483 skin reaction Effects 0.000 description 1
- 206010041232 sneezing Diseases 0.000 description 1
- 229940125379 topical corticosteroid Drugs 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/35—Allergens
- A61K39/36—Allergens from pollen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
Descrizione del brevetto per invenzione industriale avente per titolo: Description of the patent for industrial invention entitled:
“COMPOSIZIONI TRANSDERMICHE PER IMMUNOTERAPIA SPECIFICA IPOSENSIBILIZZANTE” "TRANSDERMAL COMPOSITIONS FOR SPECIFIC HYPOSENSITIZING IMMUNOTHERAPY"
La presente invenzione riguarda composizioni transdermiche per immunoterapia specifica iposensibilizzante comprendenti un antigene e acido salicilico in un eccipiente idrofobico come adiuvante. The present invention relates to transdermal compositions for specific hyposensitizing immunotherapy comprising an antigen and salicylic acid in a hydrophobic excipient as an adjuvant.
L’adiuvante secondo l’invenzione (acido salicilico in un eccipiente idrofobico, preferibilmente vaselina) apre una finestra cutanea controllata che consente agli allergeni di attraversare la cute senza manifestare la reazione mastocitaria e raggiungere il sistema immunologico e così esercitare la loro nota attività iposensibilizzante. The adjuvant according to the invention (salicylic acid in a hydrophobic excipient, preferably petroleum jelly) opens a controlled skin window that allows allergens to pass through the skin without manifesting the mast cell reaction and reach the immunological system and thus exert their known hyposensitizing activity.
Le composizioni transdermiche per immunoterapia specifica iposensibilizzante (ITS) oggetto dell’invenzione sono utili per il trattamento di pazienti allergici, che presentano tipiche malattie IgE mediate (oculorinite, asma, dermatite, orticaria e gastroenterite). The transdermal compositions for specific hyposensitizing immunotherapy (ITS) object of the invention are useful for the treatment of allergic patients, who have typical IgE mediated diseases (oculorinitis, asthma, dermatitis, urticaria and gastroenteritis).
Stato della tecnica State of the art
Le linee guida delle società scientifiche definiscono l’ITS come l’unica terapia in grado di cambiare la storia naturale della malattia. Attualmente l’ITS è somministrata prevalentemente per via sottocutanea, orale, sublinguale e intranasale. The guidelines of scientific societies define ITS as the only therapy capable of changing the natural history of the disease. ITS is currently administered mainly subcutaneously, orally, sublingually and intranasally.
È stata anche proposta la via transdermica in US 2007/0292445 per mezzo di un dispositivo che genera micro-canali nella pelle del soggetto da trattare e in WO 2007/059979, che prevede un preventivo trattamento di decheratinizzazione prima dell’applicazione dell’allergene. The transdermal route was also proposed in US 2007/0292445 by means of a device that generates micro-channels in the skin of the subject to be treated and in WO 2007/059979, which provides for a preventive decheratinization treatment before the application of the allergen.
Descrizione dell’invenzione Description of the invention
Si è ora trovato che l’acido salicilico in un eccipiente idrofobico quale vaselina è un adiuvante vantaggioso in grado di aprire un finestra cutanea controllata che consente una adeguata diffusione transcutanea dell’allergene (senza provocare nel derma la reazione mastocitaria). It has now been found that salicylic acid in a hydrophobic excipient such as petroleum jelly is an advantageous adjuvant capable of opening a controlled skin window that allows adequate transcutaneous diffusion of the allergen (without causing the mast cell reaction in the dermis).
L’invenzione fornisce pertanto composizioni transdermiche per immunoterapia specifica iposensibilizzante comprendenti un antigene e acido salicilico in un eccipiente idrofobico come adiuvante. The invention therefore provides transdermal compositions for specific hyposensitizing immunotherapy comprising an antigen and salicylic acid in a hydrophobic excipient as an adjuvant.
Le composizioni dell’invenzione sono ad esempio in forma di cerotto transdermico, preparato secondo le tecniche note nel settore. The compositions of the invention are for example in the form of a transdermal patch, prepared according to the techniques known in the field.
Può essere utilizzato un qualunque allergene di interesse nelle quantità appropriate che saranno generalmente nell’ordine dei microgrammi per cerotto. La concentrazione dell’acido salicilico nell’eccipiente idrofobico sarà di norma compresa tra 1 e 5% in peso. Any allergen of interest can be used in the appropriate quantities which will generally be in the order of micrograms per patch. The concentration of salicylic acid in the hydrophobic excipient will normally be between 1 and 5% by weight.
L’efficacia dell’ITS transcutanea mediante le composizioni dell’invenzione è stata valutata in uno studio clinico randomizzato in doppio cieco a due braccia (attivo verso placebo) condotto in pazienti in età pediatrica affetti da oculorinite allergica da graminacee. The efficacy of transcutaneous ITS using the compositions of the invention was evaluated in a two-arm randomized double-blind clinical study (active versus placebo) conducted in pediatric patients suffering from allergic oculorinitis from grasses.
La terapia di allergene attraverso la finestra cutanea indotta dall’adiuvante ha evidenziato la significativa riduzione dei sintomi e del consumo dei farmaci sintomatici nei pazienti allergici durante l’esposizione naturale dell’allergene. Allergen therapy through the skin window induced by the adjuvant has shown the significant reduction of symptoms and the consumption of symptomatic drugs in allergic patients during natural exposure of the allergen.
La terapia specifica iposensibilizzante somministrata attraverso l’apposizione di un semplice cerotto medicato contenente acido salicilico in vaselina è risultata in grado di controllare la cinetica del passaggio transcutaneo degli allergeni come dimostrato in maggior dettaglio nel seguente Esempio. The specific hyposensitizing therapy administered through the application of a simple medicated plaster containing salicylic acid in petroleum jelly was found to be able to control the kinetics of the transcutaneous passage of allergens as demonstrated in greater detail in the following Example.
Esempio Example
Gli effetti terapeutici raggiungibili mediante la somministrazione dell’ITS attualmente commercializzate possono essere ottenuti anche somministrando l’allergene mediante l’apposizione ripetuta sulla cute di un cerotto. The therapeutic effects achievable by administering the ITS currently marketed can also be obtained by administering the allergen by repeatedly affixing a patch to the skin.
Verifica clinica Clinical verification
Studio monocentrico parallelo in doppio cieco per valutare l'efficacia dell'immunoterapia specifica transcutanea, somministrata pre-stagionalmente nel trattamento della rinocongiuntivite allergica da graminacee in età pediatrica. Single-center parallel double-blind study to evaluate the efficacy of specific transcutaneous immunotherapy, administered pre-seasonally in the treatment of allergic rhinoconjunctivitis due to grasses in pediatric age.
Disegno dello studio: Study design:
in doppio cieco, randomizzato, controllato vs. placebo a 2 gruppi paralleli. double-blind, randomized, controlled vs. placebo in 2 parallel groups.
Trattamento: Treatment:
Vaccino specifico iposensibilizzante transcutaneo per graminacee, somministrato 1 volta alla settimana per 12 settimane prima dell’inizio dell’impollinazione. Il cerotto è stato mantenuto in loco per 24 ore. Specific transcutaneous hyposensitizing vaccine for grasses, administered once a week for 12 weeks before the start of pollination. The patch was kept in place for 24 hours.
Gruppi sperimentali: Experimental groups:
Gruppo A: vaccino transcutaneo Group A: transcutaneous vaccine
Gruppo B: placebo Group B: placebo
Durata complessiva del trattamento: 12 dosi settimanali Total duration of treatment: 12 weekly doses
Flow chart delle fasi cliniche effettuate: Flow chart of the clinical phases carried out:
Visita 1 di reclutamento Visit 1 for recruitment
visita clinica con dati generali ed informazioni allergiche specifiche, verifica dei criteri di inclusione ed esclusione, medicazioni precedenti, data e consenso informato, Prick test. clinical visit with general data and specific allergic information, verification of inclusion and exclusion criteria, previous medications, date and informed consent, Prick test.
Visita 2 Inizio terapia Visit 2 Start of therapy
inizio terapia e consegna del vaccino al paziente istruito initiation of therapy and delivery of the vaccine to the instructed patient
Visita 3 di fine terapia Visit 3 at the end of therapy
rilievo tollerabilità e quanto altro durante la terapia, consegna del diario. Visita 4 follow-up finale relief of tolerability and anything else during therapy, delivery of the diary. Visit 4 final follow-up
visita clinica, ritiro e controllo diari clinici, Prick test. clinical visit, collection and control of clinical diaries, Prick test.
Compilazione del RQLQ (rhinoconjunctivitis quality of life questionare). Compilation of the RQLQ (rhinoconjunctivitis quality of life questionare).
Criteri di inclusione: Inclusion criteria:
pazienti di ambo i sessi, 6 - 14 anni, con diagnosi di oculorinite e/o asma patients of both sexes, 6 - 14 years, diagnosed with oculorinitis and / or asthma
Criteri di esclusione: Exclusion criteria:
Pazienti con ipersensibilità IgE mediata (prick test positivo e/o presenza di IgE specifiche nel siero) verso fagaceae, oleaceae, urticaceae. Patients with IgE mediated hypersensitivity (positive prick test and / or presence of specific IgE in the serum) towards fagaceae, oleaceae, urticaceae.
Pazienti con allergia alimentare importante (specie molluschi e/o crostacei) o con allergia al latex. Patients with severe food allergy (especially molluscs and / or crustaceans) or with latex allergy.
Paziente già in trattamento con terapia iposensibilizzante. Patient already being treated with hyposensitizing therapy.
Mancanza di collaborazione del paziente. Lack of patient cooperation.
Altre condizioni che sconsigliano l’ITS secondo Memorandum SIAIC e/o Position Paper EAACI (1993). Other conditions that advise against ITS according to the SIAIC Memorandum and / or Position Paper EAACI (1993).
Risultati Results
Nessun paziente ha segnalato effetti collaterali durante l’esecuzione dell’immunoterapia. No patient reported side effects while performing immunotherapy.
Dai risultati riportati nella tabella sottostante si evidenzia l’efficacia The results shown in the table below show the effectiveness
della terapia transcutanea, esistono infatti significative differenze fra i due of transcutaneous therapy, there are indeed significant differences between the two
gruppi (attivo vs placebo). groups (active vs placebo).
Il gruppo attivo ha riportato un minor consumo di farmaci (antistaminico The active group reported lower drug use (antihistamine
all’inizio della stagione pollinica e corticosteroide topico alla fine). at the beginning of the pollen season and topical corticosteroid at the end).
Zirtec nasonex Zirtec nasonex
april 3<rd>0,41 0,31 April 3 <rd> 0.41 0.31
april 4<th>0,02 0,34 april 4 <th> 0.02 0.34
may 1<st>0,05 0,10 may 1 <st> 0.05 0.10
may 2nd 0,208 0,004 may 2nd 0.208 0.004
p < 0,05 = riduzione significativa p <0.05 = significant reduction
Il gruppo attivo ha segnalato una netta e significativa riduzione sia dei The active group reported a clear and significant reduction in both
sintomi respiratori sia oculari. respiratory and ocular symptoms.
<to>prur. occhi scolo nas.<pruri><to> prur. eyes runny nose. <pruri>
nas. starnuti naso ch.<diff.>nas. sneezing nose ch. <diff.>
resp.occhilacrimaz. rossi april 3rd 0,32 0,17 0,98 0,54 0,25 0,23 0,41 0,82 april 4th 0,05 0,76 0,54 0,10 0,04 0,12 0,05 0,04 may 1st 0,08 0,35 0,17 0,04 0,04 0,01 0,04 0,01 may 2nd 0,003 0,008 0,060 0,000 0,015 0,003 0,009 0,007 resp.occhilacrimaz. rossi april 3rd 0.32 0.17 0.98 0.54 0.25 0.23 0.41 0.82 april 4th 0.05 0.76 0.54 0.10 0.04 0.12 0.05 0.04 may 1st 0.08 0.35 0.17 0.04 0.04 0.01 0.04 0.01 may 2nd 0.003 0.008 0.060 0.000 0.015 0.003 0.009 0.007
p < 0,05 = riduzione significativa p <0.05 = significant reduction
Andamento stagionale del polline delle graminacee nella zona dove è Seasonal trend of grass pollen in the area where it is
stata effettuata la verifica clinica: clinical verification was carried out:
14-04/ 21-04/ 28-04/ 05-05/ 12-05/ 19-05/ 20-04 27-04 04-05 11-05 18-05 25-05 Granuli per m3 10 43 111 153 48 19 14-04 / 21-04 / 28-04 / 05-05 / 12-05 / 19-05 / 20-04 27-04 04-05 11-05 18-05 25-05 Granules per m3 10 43 111 153 48 19
L’obiettivo primario è stato raggiunto con la dimostrazione The primary objective was achieved with the demonstration
dell’efficacia terapeutica dell’immunoterapia specifica iposensibilizzante per the therapeutic efficacy of specific hyposensitizing immunotherapy for
graminacee somministrata per via transcutanea (riduzione della sintomatologia e del consumo di farmaci sintomatici durante il periodo di esposizione dei pazienti al polline). grasses administered transcutaneously (reduction of symptoms and the consumption of symptomatic drugs during the period of exposure of patients to pollen).
Sono state convalidate sia la preparazione del cerotto sia le sue modalità d’uso. Both the preparation of the patch and its methods of use have been validated.
L’assenza di reazioni cutanee durante l’esecuzione della terapia dimostra che l’appropriata concentrazione di acido salicilico in vaselina ha aperto una finestra cutanea in grado di lasciar passare la dose allergenica che si è dimostrata terapeutica senza scatenare la reazione mastocitaria nel derma. The absence of skin reactions during the execution of the therapy demonstrates that the appropriate concentration of salicylic acid in petroleum jelly has opened a skin window capable of allowing the allergenic dose to pass, which has proved therapeutic without triggering the mast cell reaction in the dermis.
Claims (3)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT001652A ITMI20081652A1 (en) | 2008-09-16 | 2008-09-16 | TRANSDERMIC COMPOSITIONS FOR HYPOSENSIBILIZING SPECIFIC IMMUNOTHERAPY |
| PCT/EP2009/006597 WO2010031519A1 (en) | 2008-09-16 | 2009-09-11 | Transcutaneous compositions for specific immuno-modulatory treatment |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT001652A ITMI20081652A1 (en) | 2008-09-16 | 2008-09-16 | TRANSDERMIC COMPOSITIONS FOR HYPOSENSIBILIZING SPECIFIC IMMUNOTHERAPY |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ITMI20081652A1 true ITMI20081652A1 (en) | 2010-03-17 |
Family
ID=40673644
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IT001652A ITMI20081652A1 (en) | 2008-09-16 | 2008-09-16 | TRANSDERMIC COMPOSITIONS FOR HYPOSENSIBILIZING SPECIFIC IMMUNOTHERAPY |
Country Status (2)
| Country | Link |
|---|---|
| IT (1) | ITMI20081652A1 (en) |
| WO (1) | WO2010031519A1 (en) |
Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0304786A2 (en) * | 1987-08-27 | 1989-03-01 | Bayer Corporation | Intranasal vaccination of horses with inactivated microorganisms or antigenic materials |
| EP0445581A1 (en) * | 1990-03-06 | 1991-09-11 | Berlin-Chemie Ag | Stable immunostimulating preparation for parenteral application, preparation and use thereof |
| WO1999011247A1 (en) * | 1997-08-29 | 1999-03-11 | Pharmaderm Laboratories, Ltd. | Biphasic lipid vesicle composition for transdermal administration of an immunogen |
| EP1201232A1 (en) * | 1999-07-27 | 2002-05-02 | Hisamitsu Pharmaceutical Co. Inc. | Patches for external use |
| EP1340496A1 (en) * | 2000-11-07 | 2003-09-03 | Hisamitsu Pharmaceutical Co. Inc. | Pharmaceutical preparation of percutaneous absorption type |
| US20040105898A1 (en) * | 1994-02-21 | 2004-06-03 | Aberdeen University, A Great Britain Corporation | Acidified nitrite as an antimicrobial agent |
| WO2005077411A2 (en) * | 2004-02-10 | 2005-08-25 | Innate Pharma | Composition and method for the treatment of carcinoma |
| US20060002959A1 (en) * | 1996-11-14 | 2006-01-05 | Government Of The United States | Skin-sctive adjuvants for transcutaneous immuization |
| EP1849477A1 (en) * | 1998-02-25 | 2007-10-31 | THE GOVERNMENT OF THE UNITED STATES, as represented by THE SECRETARY OF THE ARMY | Use of skin penetration enhancers and barrier disruption agents to enhance the transcutaneous immune response induced by ADP-ribosylating exotoxin |
-
2008
- 2008-09-16 IT IT001652A patent/ITMI20081652A1/en unknown
-
2009
- 2009-09-11 WO PCT/EP2009/006597 patent/WO2010031519A1/en active Application Filing
Patent Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0304786A2 (en) * | 1987-08-27 | 1989-03-01 | Bayer Corporation | Intranasal vaccination of horses with inactivated microorganisms or antigenic materials |
| EP0445581A1 (en) * | 1990-03-06 | 1991-09-11 | Berlin-Chemie Ag | Stable immunostimulating preparation for parenteral application, preparation and use thereof |
| US20040105898A1 (en) * | 1994-02-21 | 2004-06-03 | Aberdeen University, A Great Britain Corporation | Acidified nitrite as an antimicrobial agent |
| US20060002959A1 (en) * | 1996-11-14 | 2006-01-05 | Government Of The United States | Skin-sctive adjuvants for transcutaneous immuization |
| WO1999011247A1 (en) * | 1997-08-29 | 1999-03-11 | Pharmaderm Laboratories, Ltd. | Biphasic lipid vesicle composition for transdermal administration of an immunogen |
| EP1849477A1 (en) * | 1998-02-25 | 2007-10-31 | THE GOVERNMENT OF THE UNITED STATES, as represented by THE SECRETARY OF THE ARMY | Use of skin penetration enhancers and barrier disruption agents to enhance the transcutaneous immune response induced by ADP-ribosylating exotoxin |
| EP1201232A1 (en) * | 1999-07-27 | 2002-05-02 | Hisamitsu Pharmaceutical Co. Inc. | Patches for external use |
| EP1340496A1 (en) * | 2000-11-07 | 2003-09-03 | Hisamitsu Pharmaceutical Co. Inc. | Pharmaceutical preparation of percutaneous absorption type |
| WO2005077411A2 (en) * | 2004-02-10 | 2005-08-25 | Innate Pharma | Composition and method for the treatment of carcinoma |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2010031519A8 (en) | 2010-05-27 |
| WO2010031519A1 (en) | 2010-03-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6768733B2 (en) | Treatment of allergic rhinitis using a combination of mometasone and olopatadine | |
| Shakya et al. | Cutaneous vaccination with coated microneedles prevents development of airway allergy | |
| ES2775425T3 (en) | Prader-Willi syndrome treatment procedure | |
| JP2014528474A5 (en) | ||
| US20240024304A1 (en) | Methods of managing conditioned fear with neurokinin receptor antagonists | |
| BRPI0804623B8 (en) | use of therapeutic human albumin for the preparation of a drug for the treatment of patients suffering from cognitive disorders | |
| JP2010538066A5 (en) | ||
| ITMI20081652A1 (en) | TRANSDERMIC COMPOSITIONS FOR HYPOSENSIBILIZING SPECIFIC IMMUNOTHERAPY | |
| JP7150409B2 (en) | An agent for completely curing allergic rhinitis (hay fever) by isolating IgE antibodies attached to mast cells in the nasal mucosa. | |
| JP2014517038A5 (en) | ||
| ES2952610T3 (en) | Methods to treat or alleviate mental disorders and associated symptoms | |
| JP6770091B2 (en) | Compositions and Methods for Treating Sinous Mucosal Diseases with Nicotinic Acetylcholine Receptor Agonists | |
| RU2463015C1 (en) | Method of treating acute and chronic deep caries of teeth with complex medication | |
| JP2014528458A (en) | Treatment of rhinitis | |
| KV K et al. | Study of effect of intravenous iron sucrose in the treatment of puerperal anemia | |
| Bezhanyan | Immunotherapy for the Treatment of Allergic Diseases | |
| JP6153193B2 (en) | Pharmaceutical composition for prevention or treatment of allergic diseases | |
| Rafiq | Isolated periorbital angio-oedema induced by aspirin: a case report and review of the literature | |
| Aggarwal et al. | ASSESSMENT OF EFFICACY OF MONTELUKAST AND PSEUDOEPEDRINE IN TREATING PATIENTS OF ALLERGIC RHINITIS: A COMPARATIVE STUDY | |
| Arasi et al. | Pre-Coseasonal vs Perennial Sublingual Immunotherapy for Seasonal Allergens Dosing Regimen: Long-Term Benefits, Adherence, and Cost-Effectiveness—Is There a Difference? | |
| Rosu et al. | Interrelations Between Anesthetic Substances, General Condition of the Patient and Implant Rehabilitation Procedure | |
| TW202120074A (en) | Uses of 4-hydroxybenzaldehyde in treating inflammatory bowel diseases | |
| Cooperation Group for Phase IV Clinical Study of Levofloxacin | The clinical efficacy and safety of intravenous levofloxacin in the treatment of 4888 patients with bacterial infections: a multi-center trial | |
| Achar et al. | Clinical efficacy and tolerability of valacyclovir versus acyclovir in treatment of herpes zoster | |
| Massanari et al. | Addition of omalizumab improved functional health status in patients with impaired quality of life associated with moderate-severe persistent allergic asthma |